Belatacept biosimilar (Alphamab)

贝拉西普生物类似药（康宁杰瑞）

Report date: 2026/03/17 20:00:15

Base Information

Drug NameBelatacept biosimilar (Alphamab)
Drug Alias Name贝他西普生物仿制药（康宁杰瑞）重组人CTLA-4变体Fc融合蛋白（康宁杰瑞）贝拉西普生物仿制药（康宁杰瑞）KN-019
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsRejection of renal transplantationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Alphamab Co LtdJiangsu Alphamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsRejection of renal transplantation

Other Information

ATC CodeL04AA28
Related LinksN/A